Breton Hill Capital Ltd. boosted its stake in shares of Pfizer, Inc. (NYSE:PFE) by 16.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 385,937 shares of the biopharmaceutical company’s stock after purchasing an additional 53,571 shares during the quarter. Pfizer makes up 2.4% of Breton Hill Capital Ltd.’s investment portfolio, making the stock its 2nd biggest holding. Breton Hill Capital Ltd.’s holdings in Pfizer were worth $12,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Northstar Group Inc. increased its holdings in Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares during the period. Stone House Investment Management LLC increased its holdings in Pfizer by 0.9% during the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares during the period. Naples Global Advisors LLC increased its holdings in Pfizer by 0.3% during the 1st quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares during the period. Alpha Windward LLC increased its holdings in Pfizer by 1.1% during the 1st quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 89 shares during the period. Finally, Asset Planning Services Ltd. increased its holdings in Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the period. Institutional investors own 69.00% of the company’s stock.
In related news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at $4,492,216. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://stocknewstimes.com/2017/09/18/breton-hill-capital-ltd-raises-holdings-in-pfizer-inc-pfe.html.
PFE has been the topic of several recent research reports. Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank restated a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, BidaskClub downgraded Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $37.83.
Shares of Pfizer, Inc. (PFE) traded down 0.071% during mid-day trading on Monday, hitting $35.335. The company had a trading volume of 4,792,436 shares. The stock’s 50-day moving average is $33.64 and its 200-day moving average is $33.53. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84. The stock has a market cap of $210.15 billion, a price-to-earnings ratio of 25.849 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 earnings per share. Equities analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.62%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.